Implantable Exenatide Delivery Device Lowers HbA1c in T2DMImplantable Exenatide Delivery Device Lowers HbA1c in T2DM
The rationale behind the subcutaneous drug-delivery platform is to offer patients an alternative to regular life-long injections and improve patient compliance and convenience, according to study investigators. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

MassDevice.com +3 | The top 3 medtech stories for August 19, 2015
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.   3. Masimo takes over Tony Stark’s headquarters Masimo moved its headquarters to a Hollywood-hotspot at 52 Discovery in Irvine, Calif., a location often used in films to represent upscale corporate headquarters. The rotund glass front entrance has served as a backdrop for multiple Hollywood ...
Source: Mass Device - August 19, 2015 Category: Medical Equipment Authors: MassDevice Tags: Blog Plus 3 Source Type: news

Diabetes: Intarcia’s implantable drug pump tops Merck’s Januvia
Intarcia Therapeutics yesterday unveiled top-line results from a year-long trial of an implantable drug pump for Type II diabetics, saying its ITCA 650 treatment proved superior to its comparator, Merck‘s (NYSE:MRK) Januvia. Fifty-two week results from the Phase III Freedom-2 trial met all primary and secondary endpoints, “demonstrating superiority over Januvia at every measured time point,” Intarcia said. The matchstick-sized, miniature osmotic pump reduced glycated hemoglobin (HbA1c) levels and weight in patients in the study, the company said. The subcutaneous ITCA 650 is designed to deliver the ...
Source: Mass Device - August 19, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Diabetes Drug Pumps Intarcia Therapeutics newtag Source Type: news

Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its...
Delpor has exclusive rights to the patented technology and has several product candidates in development, including 3-6 month formulations of exenatide, liraglutide, and basal insulin.(PRWeb April 23, 2015)Read the full story at http://www.prweb.com/releases/2015/04/prweb12671977.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 24, 2015 Category: Pharmaceuticals Source Type: news

Byetta, Victoza, Bydureon: Diabetes drugs and weight loss
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - April 11, 2015 Category: Consumer Health News Source Type: news

Real-world usage and cost of exenatide and liraglutide
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2015 Category: Drugs & Pharmacology Source Type: news

Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics...
Hundreds of Byetta lawsuits and other product liability claims involving incretin mimetic diabetes drugs are currently pending in the federal litigation underway in California.(PRWeb December 21, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12409444.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 22, 2014 Category: Pharmaceuticals Source Type: news

Diabetes Drug Litigation Prepares to Discuss Byetta Lawsuits, Claims...
The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer caused by incretin mimetic...(PRWeb December 07, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12376827.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 7, 2014 Category: Pharmaceuticals Source Type: news

New Order Issued in Federal Incretin Mimetic Litigation, Where...
The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer caused by incretin mimetic...(PRWeb December 01, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12363707.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 2, 2014 Category: Pharmaceuticals Source Type: news

California Federal Court Overseeing Byetta Lawsuits, Other Incretin...
The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer after taking incretin...(PRWeb November 23, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12344447.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 23, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: Plaintiffs in Federal Diabetes Drug Litigation...
The Firm is evaluating Byetta lawsuits and other product liability claims that allege incretin mimetic diabetes drugs caused patients to develop pancreatic cancer, pancreatitis and thyroid cancer.(PRWeb November 11, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12318604.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 12, 2014 Category: Pharmaceuticals Source Type: news

Diabetes Drug Claims Near 550 Mark in Incretin Mimetic Litigation,...
The Firm is investigating Byetta lawsuits and other legal claims that allege pancreatic cancer, pancreatitis and thyroid cancer caused by incretin mimetics, a Type 2 diabetes drug class.(PRWeb November 02, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12294498.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 2, 2014 Category: Pharmaceuticals Source Type: news

Delpor Awarded $220K NIH Grant for 3-month Exenatide Implant for the...
The NIDDK funds Delpor’s efforts to utilize its NANOPOR technology in developing a matchstick-size subcutaneous implant device capable of delivering exenatide for 3-12 months through passive diffusion(PRWeb October 17, 2014)Read the full story at http://www.prweb.com/releases/2014/10/prweb12247910.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 17, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics...
The Firm is evaluating Byetta lawsuits and other legal claims that allege the use of diabetes drugs called incretin mimetics caused patients to develop pancreatic cancer, pancreatitis or thyroid...(PRWeb October 08, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12234584.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 9, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuits Move Forward, With New Ruling Issued in Federal...
The Firm is evaluating Byetta lawsuits and other product liability claims that allege incretin mimetic diabetes drugs caused patients to develop pancreatic cancer, pancreatitis and thyroid cancer.(PRWeb September 24, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12196939.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 25, 2014 Category: Pharmaceuticals Source Type: news